Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice
Gen Chen,Ning An,Jingling Shen,Huinan Chen,Yunjie Chen,Jia Sun,Zhicheng Hu,Junhui Qiu,Cheng Jin,Shengqu He,Lin Mei,Yanru Sui,Wanqian Li,Peng Chen,Xueqiang Guan,Maoping Chu,Yang Wang,Litai Jin,Kwonseop Kim,Xiaokun Li,Weitao Cong,Xu Wang
DOI: https://doi.org/10.1038/s41467-023-36895-1
IF: 16.6
2023-03-04
Nature Communications
Abstract:Abstract Fibroblast growth factor-18 (FGF18) has diverse organ development and damage repair roles. However, its role in cardiac homeostasis following hypertrophic stimulation remains unknown. Here we investigate the regulation and function of the FGF18 in pressure overload (PO)-induced pathological cardiac hypertrophy. FGF18 heterozygous ( Fgf18 +/− ) and inducible cardiomyocyte-specific FGF18 knockout ( Fgf18-CKO ) male mice exposed to transverse aortic constriction (TAC) demonstrate exacerbated pathological cardiac hypertrophy with increased oxidative stress, cardiomyocyte death, fibrosis, and dysfunction. In contrast, cardiac-specific overexpression of FGF18 alleviates hypertrophy, decreased oxidative stress, attenuates cardiomyocyte apoptosis, and ameliorates fibrosis and cardiac function. Tyrosine-protein kinase FYN (FYN), the downstream factor of FGF18, was identified by bioinformatics analysis, LC-MS/MS and experiment validation. Mechanistic studies indicate that FGF18/FGFR3 promote FYN activity and expression and negatively regulate NADPH oxidase 4 (NOX4), thereby inhibiting reactive oxygen species (ROS) generation and alleviating pathological cardiac hypertrophy. This study uncovered the previously unknown cardioprotective effect of FGF18 mediated by the maintenance of redox homeostasis through the FYN/NOX4 signaling axis in male mice, suggesting a promising therapeutic target for the treatment of cardiac hypertrophy.
multidisciplinary sciences